Innate recognition of bacteria: Engagement of multiple receptors

Critical Reviews in Immunology

Volumn 22, Issue 4, 2002, Pages 251-268

  Triantafilou, Martha ^a   Brandenburg, Klaus ^b   Gutsmann, Thomas ^b   Seydel, Ulrich ^b   Triantafilou, Kathy ^a  

^a UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^b RESEARCH CENTER BORSTEL   (Germany)

Author keywords

Innate recognition; LPS; LPS activation cluster; TLR4; TREM 1

Indexed keywords

CD14 ANTIGEN; DECAY ACCELERATING FACTOR; INTEGRIN; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE BINDING PROTEIN; POTASSIUM ION; PROTEIN; PROTEIN ADAM 10; PROTEIN RP105; PROTEIN TREM 1; RECEPTOR; THROMBOCYTE ACTIVATING FACTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

HUMAN; IMMUNE SYSTEM; MICROBIOLOGICAL EXAMINATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; REVIEW;

ANIMALS; BACTERIA; HUMANS; IMMUNITY, NATURAL; LIPOPOLYSACCHARIDES; MODELS, BIOLOGICAL; RECEPTORS, IMMUNOLOGIC;

EID: 0036963357     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (118)

1. Zahringer U, Lindner B, Rietschel E. Chemical structure of lipid A. Recent methodical advances towards the complete structural analysis of a biologically active molecule. In: Morrison DC, Brade H, Opal S, Vogel SN, editors. Endotoxin in health and disease. New York: Marcel Dekker, 1999.
2. Schromm A, Bradenburg K, Loppnow H, Moran AP, Koch MHJ, Rietschel E, Seydel U. Biological activities of lipopolysaccharides are determined by the shape of their lipid A portion. Eur J Biochem 2000; 267:2008-2013.
3. Seydel U, Ulmer AJ, Uhlig S, Rietschel E. Membrane structure in disease and drug therapy. In: Zimmer G, editor. Endotoxin in health and disease. New York: Marcel Dekker, 1999: 217-252.
4. Bradenburg K, Mayer H, Koch MHJ, Weckesser J, Rietschel E, Seydel U. Influence of the supramolecular structure of free lipid A on its biological activity. Eur J Biochem 1993; 218:555-563.
5. Israelachvilli JN. Intermolecular and surface forces. London: Academic Press, 1991:366-394.
6. Brandenburg K, Seydel U, Schromm A, Loppnow H, Koch MHJ, Rietschel E. Conformation of lipid A, the endotoxic center of bacterial lipopolysaccharide. J Endotoxin Res 1996; 3:173-178.
7. Schromm A, Brandenburg K, Loppnow H, Zahringer U, Rietschel E, Carroll SF, Koch MHJ, Kusumoto S, Seydel U. The charge of endotoxin molecules influences their conformation and interleukin-6 inducing capacity. J Immunol 1998; 161:5464-5471.
8. Seydel U, Oikawa M, Fukase K, Kusumoto S, Brandenburg K. Intrinsic conformation of lipid A is responsible for agonistic and antagonistic activity. Eur J Biochem 2000; 267:3032-3039.
9. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (Lps) and Lps binding-protein. Science 1990; 249:1431-1433.
10. Ulevitch RJ, Tobias PS. Recognition of endotoxin by cells leading to transmembrane signaling. Curr Opin Immunol 1994; 6:125-130.
11. Hailman E, Lichenstein HS, Wurfel MM, Miller DS, Johnson DA, Kelley M, Busse LA, Zukowski MM, Wright SD. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med 1994; 179:269-277.
12. Lee JD, Kato K, Tobias PS, Kirkland TN, Ulevitch RJ. Transfection of CD14 into 70z/3 cells dramatically enhances the sensitivity to complexes of lipopolysaccharide (LPS) and LPS binding-protein. J Exp Med 1992; 175:1698-1705.
13. Pugin J, Heumann D, Tomasz A, Kravchenko VV, Akamatsu Y, Nishijima M, Glauser MP, Tobias PS, Ulevitch RJ. CD14 is a pattern-recognition receptor. Immunity 1994; 1:509-516.
14. Haziot A, Ferrero E, Kontgen F, Hijiya N, Yamamoto S, Silver J, Stewart CL, Goyert SM. Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity 1996; 4:407-414.
15. Lynn WA, Liu Y, Golenbock DT. Neither CD14 nor serum is absolutely necessary for activation of mononuclear phagocytes by bacterial lipopolysaccharide. Infect Immun 1993; 61:4456-4461.
16. Blondin C, Ledur A, Cholley B, Caroff M, HaeffnerCavaillon N. Lipopolysaccharide complexed with soluble CD14 binds to normal human monocytes. Eur J Immunol 1997; 27:3303-3309.
17. Wright SD, Jong MTC. Adhesion-promoting receptors on human macrophages recognise Escherichia coli by binding to lipopolysaccharide. J Exp Med 1986; 164:1876-1882.
18. Wright SD. Adhesion-promoting receptors on phagocytes. Agents Actions 1991; 35:23-27.
19. Wright SD, Ramos RA, Hermanowskivosatka A, Rockwell P, Detmers PA. Activation of the adhesive capacity of cr3 on neutrophils by endotoxin - dependence on lipopolysaccharide binding-protein and cd14. J Exp Med 1991; 173:1280-1286.
20. Troelstra A, de Graaf-Miltenburg LAM, van Bommel T, Verhoef J, Van Kessel KPM, Van Strijp JAG. Lipopolysaccharide-coated erythrocytes activate human neutrophils via CD14 while subsequent binding is through CD11b/CD18. J Immunol 1999; 162:4220-4225.
21. Medvedev AE, Flo T, Ingalls RR, Golenbock DT, Teti G, Vogel SN, Espevik T. Involvement of CD14 and complement receptors CR3 and CR4 in nuclear factor-kappa B activation and TNF production induced by lipopolysaccharide and group B streptococcal cell walls. J Immunol 1998; 160:4536-4542.
22. Ingalls R, Monks B, Savedra R, Christ WJ, Delude RL, Medvedev AE, Espevik T, Golenbock DT. CD11/CD18 and CD14 share a common Lipid A signalling pathway. J Immunol 1998; 161:5413-5420.
23. Ingalls RR, Arnaout MA, Golenbock D. Outside-in signalling by lipopolysaccharide through a tailless integrin. J Immunol 1997; 159:433-440.
24. Ingalls RR, Golenbock DT. CD11c/CD18, a transmembrane signaling receptor for lipopolysaccharide. J Exp Med 1995; 181:1472-1479.
25. Lei M-G, Qureshi N, Morrison DC. Specific endotoxin lipopolysaccharide binding protein on murine splenocytes. J Immunol 1988; 141:996-1005.
26. Dziarski R. Peptidoglycan and lipopolysaccharide bind to the same binding site on lymphocytes. J Biol Chem 1991; 266:4719-4725.
27. Hara-Kuge S, Amano F, Nishijima M, Akamatsu Y. Isolation of a lipopolysaccharide (LPS)-resistant mutant, with defective LPS binding, of cultured macrophage-like cells. J Biol Chem 1990; 265:6606-6610.
28. Kirkland TN, Virea GD, Kuus-Reichel T, Multer FK, Kim SY, Ulevitch R, Tobias P. Identification of lipopolysaccharide binding proteins in 70Z/3 cells by photoaffinity crosslinking. J Biol Chem 1990; 265:9520-9525.
29. Kirikae T, Inada K, Hirata M, Yoshida M, Kondo S, Hisatsune K. Identification of Re lipopolysaccharide-binding protein on murine erythrocyte membrane. FEMS Microbiol Immunol 1988; 32:33-44.
30. El-Samalouti VT, Schletter J, Brade H, Brade L, Kusumoto S, Rietschel E, Flad HD, Ulmer AJ. Detection of lipopolysaccharide (LPS)-binding membrane proteins by immuno-coprecipitation with LPS and anti-LPS antibodies. Eur J Biochem 1997; 250:418-424.
31. Triantafilou K, Triantafilou M, Dedrick RL. Interactions of bacterial lipopolysaccharide and peptidoglycan with a 70kDa and an 80kDa protein on the cell surface of CD14 positive and CD14 negative cells. Hum Immunol 2001; 62:50-63.
32. Poltorak A, He XL, Smirnova I, Liu MY, VanHuffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, et al. Defective LPS signaling in C3H/Hej and C57BL/10ScCr mice: Mutations in TLR4 gene. Science 1998; 282:2085-2088.
33. Qureshi ST, Lariviere L, Leveque G, Clermont S, Moore KJ, Gros P, Malo D. Endotoxin-tolerant mice have mutations in toll-like receptor 4 (TLR4). J Exp Med 1999; 189:615-625.
34. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda T, Akira S. Cutting edge: Toll-like receptor 4 (TLR4) deficient mice are hyporesponsive to lipopolysaccharide: Evidence for TLR4 as the LPS gene product. J Immunol 1999; 162:3749-3752.
35. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatze/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996; 86:973-975.
36. Williams MJ, Rodriguez D, Kimbell A, Eldon ED. The 18-wheeler mutation reveals complex antibacterial gene regulation in Drosophila host defense. EMBO J 1997; 16:6120-6125.
37. Medzhitov R, Preston-Hurlburt P, Janeway CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388:394-397.
38. Chow JC, Young DW, Golenbock D, Christ WJ, Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999; 274:10689-10692.
39. Lien E, Means TK, Heine H, Yoshimura A, Kusumoto S, Fukase K, Fenton MJ, Oikawa M, Qureshi N, Monks B, et al. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest 2000; 105:497-504.
40. Tapping RI, Akashi S, Miyake K, Godowski PJ, Tobias PS. Toll-like receptor 4, but not toll-like receptor 2, is a signalling receptor for Escherichia and Salmonella lipopolysaccharides. J Immunol 2000; 165:5780-5787.
41. Shoham S, Huang C, Chen JM, Golenbock DT, Levitz SM. Toll-like receptor 4 mediates intracellular signalling without TNF-alpha release in response to Cryptococcus neoformans polysaccharide capsule. J Immunol 2001; 166:4620-4626.
42. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, Walsh EE, Freeman MW, Golenbock DT, Anderson LJ, et al. Pattern recognition receptors TLR4 and CD14 mediate responses to respiratory syncytial virus. Nat Immunol 2000; 1:398-401.
43. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999; 189:1777-1782.
44. Akashi S, Shimazu R, Ogata H, Nagai Y, Takeda K, Kimoto M, Miyake K. Cutting edge: Cell surface expression and lipopolysaccharide signalling via the Toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages. J Immunol 2000; 164:3471-3475.
45. Akashi S, Ogata H, Kirikae F, Kirikae T, Kawasaki K, Nishijima M, Shimazu R, Nagai Y, Fukudome K, Kimoto M, et al. Regulatory roles for CD14 and phosphatidylinositol in the signalling via Toll-like receptor 4-MD-2. Biochem Biophys Res Commun 2000; 268:172-177.
46. da Silva Correia J, Ulevitch RJ. MD-2 and TLR4 N-linked glycosylations are important for a functional lipopolysaccharide receptor. J Biol Chem 2002; 277:1845-1854.
47. Yang RB, Mark MR, Gray A, Huang A, Xie MH, Zhang F, Goddard A, Wood WI, Gurnay AL, Godowski PJ. Toll-like receptor-2 mediates lipopolysaccharide-included cellular signalling. Nature 1998; 395:284-288.
48. Kirschning CJ, Wesche H, Ayers TM, Rothe M. Human Toll-like receptor 2 confers responsiveness to bacterial lipopolyssacharide. J Exp Med 1998; 188:2091-2097.
49. Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ. Repurification of lipopolysaccharide eliminates signalling through both human and murine toll-like receptor 2. J Immunol 2000; 165:618-622.
50. Yoshimura A, Lien E, Ingalls R, Tuomanen E, Dziarski R, Golenbock DT. Cutting edge: Recogntion of gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol 1999; 163:1-5.
51. Werts C, Tapping RI, Mathison JC, Chuang TH, Kravchenko V, Saint Girons I, Haake DA, Godowski PJ, Hayashi F, Ozinsky A, et al. Leptospiral lipopolysaccharide activates cells through a TLR-2-dependent mechanism. Nat Immunol 2001; 2:346-352.
52. Means TK, Lien E, Yoshimura A, Wang Y, Golenbock DT, Fenton MJ. The CD14 ligands Lipoarabinomannan and lipopolysaccharide differ in their requirement for Toll-like receptors. J Immunol 1999; 163:6748-6755.
53. Ozinsky A, Underhill DM, Fontenot JD, Hajjar AM, Smith KD, Wilson CB, Schroeder L, Aderem A. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. Proc Natl Acad Sci USA 2000; 97:13766-13771.
54. Flo T, Halaas O, Lien E, Ryan L, Teti G, Golenbock DT, Sundan A, Espevik T. Human Toll-like receptor 2 mediates monocyte activation by Listeria monocytogenes, but not by Group B Streptococci or lipopolysaccharide. J Immunol 2000; 164:2064-2069.
55. Hirschfeld M, Kirschning CJ, Schwandner R, Wesche H, Weis JH, Wooten RM, Weis JJ. Cutting edge: Inflammatory signalling by Borrelia burgdorferi lipoproteins is mediated by Toll-like receptor 2. J Immunol 1999; 163:2382-2386.
56. Lien E, Sellati T, Yoshimura A, Flo T, Rawadi G, Finberg RW, Carroll JD, Espevik T, Ingalls R, Radolf JD, et al. Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J Biol Chem 1999; 274:33419-33425.
57. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413:732-738.
58. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, Aderem A. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001; 410:1099-1103.
59. Hemni H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, et al. A Toll-like receptor recognises bacterial DNA. Nature 2000; 408:740-745.
60. Hajjar AM, O'Mahony DS, Ozinsky A, Underhill DM, Aderem A, Klebanoff SJ, Wilson CB. Functional interactions between toll-like receptor (TLR) 2 and TLR1 or TLR6 in response to phenol-soluble modulin. J Immunol 2001; 166:15-19.
61. Henneke P, Takeuchi O, Van Strijp JA, Guttormsen HK, Smith JA, Schromm AB, Espevik TA, Akira S, Nizet V, Kasper DL, et al. Novel engagement of CD14 and multiple Toll-like receptors by Group B Streptococci. J Immunol 2001; 167:7069-7076.
62. El-Samalouti VT, Schletter J, Chyla I, Lentschat A, Mamat U, Brade H, Ulmer AJ, Hamann L. Identification of the 80-kDa LPS-binding protein (LMP-80): as decay-accelerating factor (DAF, CD55). FEMS Immunol Med Microbiol 1999; 23:259-269.
63. Heine H, Ulmer AJ, El-Samalouti VT, Lentschat A, Hamann L. Decay-accelerating factor (DAF/CD55) is a functional active element of the LPS receptor complex. J Endotoxin Res 2001; 7:227-231.
64. Pfeiffer A, Bottcher A, Orso E, Kapinsky M, Nagy P, Bodnar A, Spreitzer I, Liebisch G, Drobnik W, Gempel K, et al. Lipopolysaccharide and ceramide docking to CD14 provokes ligand-specific receptor clustering in rafts. Eur J Immunol 2001; 31:3153-3164.
65. Bouchon A, Dietrich J, Colonna M. Cutting edge: Inflammatory responses can be triggered byTREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 2000; 164:4991-4995.
66. Nathan C, Ding A. TREM-1: a new regulator of innate immunity in sepsis syndrome. Nat Med 2001; 7:530-532.
67. Miyake K, Yamashita Y, Ogata M, Sudo T, Kimoto M. RP105, a novel B cell surface molecule implicated in B cell activation, is a member of the leucine-rich repeat protein family. J Immunol 1995; 154:3333-3340.
68. Ogata H, Su I, Miyake K, Nagai Y, Akashi S, Mecklenbrauker I, Rajewsky K, Kimoto M, Tarakhovsky A. The Toll-like receptor protein RP105 regulates lipopolysaccharide signalling in B cells. J Exp Med 2000; 192:23-29.
69. Lemjabbar H, Basbaum C. Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcus aureus in epithelial cells. Nat Med 2002; 8:41-46.
70. Blunck R, Scheel O, Muller M, Bradenburg K, Seitzer U, Seydel U. New insights into endotoxin-induced activation of macrophages: Involvement of a K+ channel in transmembrane signaling. J Immunol 2001; 166:1009-1015.
71. + channel is involved in LPS signaling. J Endotoxin Res 2001; 7:243-247.
72. Martin DK, Bootcov MR, Campbell TJ, French PW, Breit SN. Human macrophages contain a stretch-sensitive potassium channel that is activated by adherence and cytokines. J Membr Biol 1995; 147:305-315.
73. Haslberger A, Romanin C, Koerber R. Membrane potential modulates release of tumor necrosis factor in lipopolysaccharide-stimulated mouse macrophages. Mol Biol Cell 1992; 3:451-460.
74. Walev I, Reske M, Palmer A, Valeva A, Bhakdi S. Potassium-inhibited processing of IL-1 beta in human monocytes. EMBO J 1995; 14:1607-1614.
75. Maruyama N, Kakuta Y, Yamauchi K, Ohkawara Y, Aizawa T, Ohrui T, Nara M, Oshiro T, Ohno I, Tamura G. Quinine inhibits production of tumor necrosis factor from human aleveolar macrophages. Am J Respir Cell Mol Biol 1994; 10:514-520.
76. Lowry MA, Goldber JI, Belosevic M. Induction of nitric oxide (NO) synthesis in murine macrophages requires potassium channel activity. Clin Exp Immunol 1998; 111:97-103.
77. McKinney LC, Gallin EK. Effect of adherence, cell morphology, and lipopolysaccharide on potassium conductance and passive membrane properties of murine macrophage J774.1 cells. J Membr Biol 1990; 116:47-56.
78. Hoang LM, Chen C, Mathers DA. Lipopolysaccharide rapidly activates K+ channels at the intracellular membrane face of rat cerebral artery smooth muscle cells. Neurosci Lett 1997; 231:25-28.
79. Loppnow H, Rietschel E, Brade H, Schonbeck U, Libby P, Wang MH, Heiner H, Feist W, Durrbaum-Landmann I, Ernst M, Brandt E, Grage-Griebenow E, Ulmer AJ, Campos-Portuguez S, Schade UF, Kirikae T, Kusumoto S, Krauss JH, Mayer H, Flad H. In: Levin J, Alving CR, Munford RS, Stutz P, editors. Lipid A precursor Ia (compound 406) and Rhodobacter capsulatus lipopolysaccharide: a potent endotoxin antagonists in the human system in vitro. Amsterdam: Elsevier, 1993: 337 pp.
80. Gegner JA, Ulevitch RJ, Tobias PS. Lipopolysaccharide (LPS) Signal-transduction and clearance - dual roles for LPS binding-protein and membrane CD14. J Biol Chem 1995; 270:5319-5325.
81. Jackson SK, James PE, Rowlands CC, Mile B. Binding of endotoxin to macrophages: interactions of spin-labelled saccharide residues. Biochim Biophys Acta 1992; 1135:165-170.
82. Dijkstra J, Bron R, Wilschut J, de Haan A, Ryan JL. Activation of murine lymphocytes by lipopolysaccharide incorporated in fusogenic, reconstituted influenza virus envelopes (virosomes). J Immunol 1996; 157:1028-1036.
83. Shinitzky M. In: Shinitzky M, editor. Membrane fluidity and cellular functions. Boca Raton: CRC Press, 1984: 1 p.
84. Cossins AR, Sinensky M. Adaptation of membranes to temperature, pressure, and exogenous lipids. In: Shinitzky M, editor. Physiology of membrane fluidity. Boca Raton: CRC Press, 2000: pp. 1-20.
85. Golenbock DT, Liu Y, Millham FH, Freeman MW, Zoeller RA. Surface expression of human CD14 in Chinese hamster ovary fibroblasts imparts macrophage-like responsiveness to bacterial endotoxin. J Biol Chem 1993; 268:22055-22059.
86. Mattsby-Baltzer A, Roseanu A, Motas C, Elverfors J, Engberg I, Hanson LA. Lactoferrin or a fragment thereof inhibits the endotoxin-induced interleukin-6 response in human monocytic cells. Pediatr Res 1996; 40:257-262.
87. Gutsmann T, Haberer N, Carroll SF, Seydel A. Interactions between lipopolysaccharidde (LPS), LPS-binding protein (LBP), and planar membranes. Biol Chem 2001; 382:425-434.
88. Gutsmann T, Mueller M, Carroll SF, MacKenzie RC, Wiese A, Seydel U. Dual role of lipopolysaccharide (LPS)-binding protein in neutralization of LPS and enhancement of LPS-induced activation of mononuclear cells. Infect Immun 2001; 69:6942-6950.
89. Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison J, Tobias P, Ulevitch R. Structure and function of lipopolysaccharide binding protein. Science 1990; 249:1429-1433.
90. Triantafilou K, Triantafilou M, Ladha S, Mackie A, Fernandez N, Dedrick RL, Cherry RJ. Fluorescence recovery after photobleaching reveals that lipopolysaccharide rapidly transfers from CD14 to heat shock proteins 70 and 90 on the cell membrane. J Cell Sci 2001; 114:2535-2545.
91. Triantafilou K, Triantafilou M, Dedrick RL. A CD14-independent LPS receptor duster. Nat Immunol 2001; 4:338-345.
92. Kaur I, Voss SD, Gupta RS, Schell K, Fisch P, Sondel PM. Human peripheral γδ T cells recognise hsp 60 molecules on Daudi Burkitt's lymphoma cells. J Immunol 1993; 150:475-478.
93. Multhoff G, Otzler C, Jennen L, Schmidt J, Ellwart J, Issels R. Heat shock protein 72 on tumour cells. J Immunol 1997; 158:4341-4350.
94. Tsuboi N, Ishikawa M, Tamura Y, Takayama S, Tobioka H, Matsuura A, Hirayoshi K, Nagata K, Sato N, Kikuchi K. Monoclonal antibody specifically reacting against 73-kiolodalton heat shock protein: possible expression on mammalian cell surface. Hybridoma 1994; 48:2798-2804.
95. Takashima S, Sato N, Kishi A, Tamura Y, Hirai I, Torigoe T, Yagihashi A, Takahashi SSS, Kudo R, Kikuchi K. Involvement of peptide antigens in the cytotoxicity between 70 kDa heat shock cognate protein-like molecule and CD3+, CD4-, CD8-, TCRαβ-killer T-cells. J Immunol 1996; 157:3391-3395.
96. Breloer M, Fleischer B, von Bonin A. In vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins. J Immunol 1999; 162:3141-3147.
97. Byrd CA, Bornmann W, Erdjument-Bromage H, Tempst P, Pavletich N, Rosen N, Nathan CF, Ding A. Heat shock 90 mediates macrophage activation by Taxol and bacterial lipopolysaccharide. Proc Natl Acad Sci USA 1999; 96:5645-5650.
98. Moriuchi M, Moriuchi H, Turner W, Fauci AS. Exposure to bacterial products renders macrophages highly susceptible to T-tropic HIV-1. J Clin Invest 1998; 102:1540-1550.
99. Juffermans NP, Weijer S, Verbon A, Speelman P, van der Poll T. Expression of human immunodeficiency virus coreceptors CXC chemokine receptor 4 and CC chemokine receptor 5 on monocytes is down-regulated during human endotoxemia. J Infect Dis 2002; 185:986-989.
100. Pralle A, Keller P, Florin EL, Simons K, Horber JKH. Sphingolipid-cholesterol rafts diffuse as small entities in the plasma membrane of mammalian cells. J Cell Biol 2000; 148:997-1007.
101. Vereb G, Matko J, Vamosi G, Ibrahim SM, Magyar E, Varga S, Szollosi J, Jenei A, Gaspar R, Waldmann TA, et al. Cholesterol-dependent clustering of IL-2Ra and its colocalisation with HLA and CD48 on T lymphoma cells suggest their functional association with lipid rafts. Proc Natl Acad Sci USA 2000; 97:6013-6018.
102. Triantafilou M, Miyake K, Golenbock D, Triantafilou K. Mediators of the innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J Cell Sci 2002; 115:2603-2611.
103. Jack RS, Fan XL, Bernheiden M, Rune G, Ehlers M, Weber A, Kirsch G, Mentel R, Furli B, Freudenberg M, et al. Lipopolysaccharide-binding protein is required to combat a murine Gram-negative bacterial infection. Nature 1997; 389:742-745.
104. Tobias P, Soldau K, Ulevitch RJ. Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide binding protein. J Biol Chem 1989; 264:10867-10871.
105. Tobias PS, Soldau K, Ulevitch RJ. Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum. J Exp Med 1986; 164:785-793.
106. Schromm AB, Brandenburg K, Rietschel ET, Flad HD, Carroll SF, Seydel U. Lipopolysaccharide binding protein (LBP) mediates CD14-independent intercalation of lipopolysaccharide into phospholipid membranes. FEBS Lett 1996; 399:267-271.
107. Yu B, Hailman E, Wright SD. Lipopolysaccharide binding protein and soluble CD14 catalyze exchange of phospholipids. J Clin Invest 1997; 99:318-324
108. Gutsmann T, Schromm AB, Koch MHJ, Kusumoto S, Fukase K, Oikawa M, Seydel A. Lipopolysaccharide-binding protein-mediated interaction of lipid A from different origin with phospholipid membranes. Phys Chem Chem Phys 2000; 2:4521-4528.
109. Wurfel MM, Hailman E, Wright SD. Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) By LPS-binding protein and reconstituted high-density-lipoprotein. J Exp Med 1995; 181:1748-1754.
110. Wurfel MM, Kunitake ST, Lichenstein H, Kane JP, Wright SD. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med 1994; 180:1028-1035.
111. Heumann D, Gallay P, Barras C, Zaech P, Ulevitch RJ, Tobias P, Glauser MP, Baumgartner JD. Control of lipopolysaccharide (LPS) binding and LPS-induced tumor necrosis factor secretion in human peripheral blood monocytes. J Immunol 1992; 148:3505-3512.
112. Betz Corradin S, Mauel J, Gallay P, Heumann D, Ulevitch RJ, Tobias P. Enhancement of murine macrophage binding of and response to bacterial lipopolysaccharide. J Leukocyte Biol 1992; 52:363-368.
113. Dentener M, Von Asmuth EJU, Francot GJM, Marra MN, Buurman WA. Antagonistic effects of lipopolysaccharide binding protein and bactericidal/ permeability-increasing protein on lipopolysaccharide induced cytokine release by mononuclear phagocytes: Competition for binding to lipopolysaccharide. J Immunol 1993; 151:4258-4265.
114. Schumann RR, Lamping N, Dettmer R, Schroder NW, Pfeil D, Hallatschek W, Burger R, Schum. Lipopolysaccharide-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. J Clin Invest 1998; 101:2065-2071.
115. Hirata M, Shimomura Y, Yoshida M, Morgan JG, Palings IWD, Yen MH, Wright SC, Larrick JW. Characterization of a rabbit cationic protein (CAP18) with lipopolysaccharide-inhibitory activity. Infect Immun 1994; 62:1421-1426.
116. Lei M-G, Qureshi N, Morrison DC. Lipopolysaccharide (LPS) binding to 37 kDa and 38 kDa surface proteins on lymphoreticular cells. Immunol Lett 1988; 36:245-250.
117. Lei MG, Qureshi N, Morrison DC. Lipopolysaccharide (LPS) binding to 73 kDa and 35 kDa surface proteins on lymphoreticular cells: Preferential inhibition of LPS binding to the former by Rhodopseudomonas sphaeroides lipid A. Immunol Lett 1993; 36:245-250.
118. Hampton RY, Golenbock D, Raetz RHC. Lipid A binding sites in membranes of macrophage tumour cells. J Biol Chem 1988; 263:14802-14807.